<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02532634</url>
  </required_header>
  <id_info>
    <org_study_id>KJH-2015-01</org_study_id>
    <nct_id>NCT02532634</nct_id>
  </id_info>
  <brief_title>Ramosetron, Aprepitant, and Dexamethasone Versus Palonosetron, Aprepitant, and Dexamethasone</brief_title>
  <acronym>RAPA</acronym>
  <official_title>Comparison of Ramosetron, Aprepitant, and Dexamethasone (RAD) With Palonosetron, Aprepitant, and Dexamethasone (PAD) for Prevention of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kangdong Sacred Heart Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Catholic University of Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Korea, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kangdong Sacred Heart Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the anti-emetic effect of ramosetron plus aprepitant
      and dexamethasone with palonosetron plus aprepitant and dexamethasone in patients receiving
      highly emetogenic chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Currently, palonosetron is the clinically preferred antiemetic for Chemotherapy-induced
      nausea and vomiting (CINV).However the best 5-hydroxytryptamine 3 receptor (5-HT3R)
      antagonists for use in a triple drug combination for high emetogenic chemotherapy(HEC) has
      not yet been determined in randomized trials. Previous anti-emetic guidelines stated that the
      anti-emetic activities of 5-HT3R antagonists were similar at equivalent doses. Based on the
      meta-analysis of various 5-HT3R antagonists in double regimens, the NCCN guideline has
      suggested palonosetron as a preferred 5-HT3R antagonist in the triple antiemetic drug
      combination. But in Asia, RAD is one of the most popular treatments for HEC-treated cancer
      patients. However, the lack of clinical studies has precluded the recommendation of RAD as a
      standard regimen for HEC-induced CINV. In two previous studies conducted in Korea, RAD
      regimen showed significant efficacy for prevention of CINV which is comparable to the
      efficacy reported from the studies evaluating with PAD regimen. If the efficacy of RAD
      regimen is evidently proven by this kind of randomized multicenter-trial, RAD regimen can be
      more recommended as a standard regimen for HEC-induced CINV.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 19, 2015</start_date>
  <completion_date type="Actual">May 8, 2018</completion_date>
  <primary_completion_date type="Actual">May 8, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the overall complete response (CR) of RAD to PAD (Overall CR defined as no emesis, no rescue medication, at cycle 1</measure>
    <time_frame>0-120 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">292</enrollment>
  <condition>Cancer</condition>
  <condition>Tumors</condition>
  <arm_group>
    <arm_group_label>ramosetron, aprepitant, dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramosetron 0.3mg IV day1
Aprepitant 125mg PO qd day1, 80mg po qd day 2, 3
Dexamethasone 12mg IV or PO qd day1, 8mg PO day 2, 3, 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>palonosetron, aprepitant, dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Palonosetron 0.25mg IV day1
Aprepitant 125mg PO qd day1, 80mg po qd day 2, 3
Dexamethasone 12mg IV or PO qd day1, 8mg PO day 2, 3, 4</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramosetron, aprepitant, dexamethasone</intervention_name>
    <description>ramosetron 0.3 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4</description>
    <arm_group_label>ramosetron, aprepitant, dexamethasone</arm_group_label>
    <other_name>ramosetron(nasea)</other_name>
    <other_name>aprepitant(emend)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>palonosetron, aprepitant, dexamethasone</intervention_name>
    <description>palonosetron 0.25 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4</description>
    <arm_group_label>palonosetron, aprepitant, dexamethasone</arm_group_label>
    <other_name>palonosetron(aloxi)</other_name>
    <other_name>aprepitant(emend)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient's age is ≥ 19 years old

          -  Histologically or cytologically confirmed solid tumor

          -  Patients diagnosed as malignancy who will be treated with highly emetogenic
             chemotherapeutic agents (NCCN guideline v2.0, 2014 anti-emesis). (Cisplatin dosage is
             over 50mg/m2, combination therapy is available with other chemotherapeutic agents and
             including lymphoma)

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Available oral administration of study drugs

          -  Adequate organ functions as follows: 1) Hematologic - white blood cell count (WBC) ≥
             3000 microliter (microL) or Neutrophil≥ 1500 micro/L, Platelet ≥ 100,000/microL; 2)
             Serum Creatinine ≤ 1.5 times upper limit of normal; 3) Hepatic function - Total
             bilirubin, AST, ALT ≤2.5 times upper limit of normal, ALP ≤ 2 times upper limit of
             normal( except ALP increasing due to bone metastasis

          -  Patients with normal range of serum K, Mg and hold serum Ca over lower limit of normal
             range

          -  Patients must sign an informed consent indicating that they are aware of the
             investigational nature of the study in keeping with the policy of the hospital

        Exclusion Criteria:

          -  Patients with severe Hypertension, severe Heart disease, congenital long QT syndrome,
             bradyarrhythmia severe kidney disease(serum creatinine≥3㎎/㎗), liver disease (AST, ALT
             ≥ 2.5 times of upper normal range, ALP ≥ 2 times of upper normal range)

          -  Patients with GI obstruction, active gastric ulcer or other diseases that could
             provoke nausea and vomiting

          -  Patients who have nausea and vomiting within 1 week before chemotherapy

          -  Patients who should take steroid, antiemetics, antipsychotic agent including
             benzodiazepine, pimozide, terfenadine, astemizole, cisapride, rifampin, carbamazepine,
             phenytoin, ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin,
             ritonavir or nelfinavir, selective serotonin reuptake inhibitors,
             serotonin-norepinephrine reuptake inhibitors for the treatment of other diseases

          -  Patients with brain tumor, brain metastasis or seizure

          -  Patients receiving chemotherapy within 6 months before enrollment

          -  Patients who need radiation therapy during study period or receiving radiation therapy
             within 2 weeks before chemotherapy

          -  Patients who have known allergy or severe side effect on study drugs(5-HT3 antagonist
             and aprepitant)

          -  Pregnant or lactating women, or women who wish to become pregnant

          -  Patients with drug abuse, a mental disease and difficult to communicate with
             investigators

          -  Others whom the investigator judges inappropriate as subjects for this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Hyoung Kang, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jung Hye Kwon, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Kangdong Sacred Heart Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Vincent`S Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospita</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangbuk Samsung Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangdong Sacred Heart Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2015</study_first_submitted>
  <study_first_submitted_qc>August 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2015</study_first_posted>
  <last_update_submitted>May 8, 2018</last_update_submitted>
  <last_update_submitted_qc>May 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kangdong Sacred Heart Hospital</investigator_affiliation>
    <investigator_full_name>Kwon, Jung Hye</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>ramosetron</keyword>
  <keyword>palonosetron</keyword>
  <keyword>chemotherapy induced nausea and vomiting</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
    <mesh_term>Ramosetron</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Palonosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

